Published in Proc Natl Acad Sci U S A on July 25, 2011
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (2011) 1.81
H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A (2012) 1.28
Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci (2013) 1.21
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest (2013) 1.21
Conserved RB functions in development and tumor suppression. Protein Cell (2011) 1.15
Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem (2013) 1.12
Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep (2014) 1.04
Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front Oncol (2012) 1.02
Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. Proc Natl Acad Sci U S A (2012) 0.99
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res (2012) 0.98
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol (2016) 0.96
Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity. Nat Commun (2014) 0.94
RB1: a prototype tumor suppressor and an enigma. Genes Dev (2016) 0.93
Histone demethylase RBP2 induced by Helicobactor Pylori CagA participates in the malignant transformation of gastric epithelial cells. Oncotarget (2014) 0.88
Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells. Genes Dev (2015) 0.87
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer (2014) 0.86
Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem (2014) 0.86
ATM mediates pRB function to control DNMT1 protein stability and DNA methylation. Mol Cell Biol (2013) 0.85
RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer. PLoS One (2013) 0.83
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases. J Biol Chem (2015) 0.83
Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. Mol Carcinog (2015) 0.82
An high-throughput in vivo screening system to select H3K4-specific histone demethylase inhibitors. PLoS One (2014) 0.82
Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes. J Biol Chem (2014) 0.81
KDM5 interacts with Foxo to modulate cellular levels of oxidative stress. PLoS Genet (2014) 0.81
Antitumor mechanisms when pRb and p53 are genetically inactivated. Oncogene (2014) 0.81
Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies. Int J Endocr Oncol (2015) 0.80
Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies. World J Stem Cells (2016) 0.79
Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol (2016) 0.79
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget (2016) 0.78
RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Exp Mol Med (2016) 0.78
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. Cell Rep (2017) 0.77
The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Front Pharmacol (2017) 0.76
Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther (2016) 0.75
Kdm5/Lid Regulates Chromosome Architecture in Meiotic Prophase I Independently of Its Histone Demethylase Activity. PLoS Genet (2016) 0.75
Histone lysine demethylases in mammalian embryonic development. Exp Mol Med (2017) 0.75
KDM5 lysine demethylases are involved in maintenance of 3'UTR length. Sci Adv (2016) 0.75
The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation. Nucleic Acids Res (2016) 0.75
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype. Oncogenesis (2016) 0.75
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther (2016) 0.75
Twenty years of menin: emerging opportunities for restoration of transcription in MEN1. Endocr Relat Cancer (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Epigenetics in cancer. N Engl J Med (2008) 17.36
Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol (2001) 15.02
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol (2002) 13.87
The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol (2005) 12.70
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Effects of an Rb mutation in the mouse. Nature (1992) 11.06
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
Rb targets histone H3 methylation and HP1 to promoters. Nature (2001) 8.26
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 8.16
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Rb interacts with histone deacetylase to repress transcription. Cell (1998) 7.22
Requirement for a functional Rb-1 gene in murine development. Nature (1992) 6.87
Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 6.87
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell (2008) 6.86
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol (2004) 6.55
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell (2007) 6.04
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development (2000) 5.30
Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev (2008) 5.25
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet (2000) 5.09
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell (1994) 5.00
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol (2001) 4.39
RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell (2007) 4.34
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A (2002) 4.03
Extra-embryonic function of Rb is essential for embryonic development and viability. Nature (2003) 3.92
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature (2009) 3.13
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev (1998) 3.01
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A (2001) 2.57
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol (1996) 2.23
Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene (1994) 2.20
JmjC: cupin metalloenzyme-like domains in jumonji, hairless and phospholipase A2beta. Trends Biochem Sci (2001) 2.16
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem (1999) 2.09
Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol (1997) 2.02
Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol Cell (2008) 1.93
Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest (1997) 1.89
Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. Proc Natl Acad Sci U S A (2003) 1.74
RBP2 is an MRG15 complex component and down-regulates intragenic histone H3 lysine 4 methylation. Genes Cells (2007) 1.71
The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation. Mol Cell Biol (2008) 1.67
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Decitabine--bedside to bench. Crit Rev Oncol Hematol (2006) 1.59
Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res (2003) 1.43
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology (2009) 1.29
Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer (2006) 1.27
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) (2011) 1.26
Rearrangements involving chromosome band 11Q23 in acute leukaemia. Semin Cancer Biol (1993) 1.13
Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell (2008) 1.09
Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis. Endocr Relat Cancer (2006) 0.91
Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia. Carcinogenesis (2007) 0.90
Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene (2006) 0.83
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Signatures of mutational processes in human cancer. Nature (2013) 21.63
PyCogent: a toolkit for making sense from sequence. Genome Biol (2007) 20.64
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
An extended transcriptional network for pluripotency of embryonic stem cells. Cell (2008) 14.64
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
A protein interaction network for pluripotency of embryonic stem cells. Nature (2006) 9.63
A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science (2002) 9.59
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res (2005) 7.81
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell (2008) 6.86
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (2005) 6.86
New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature (2008) 6.82
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science (2008) 6.66
IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev (2002) 6.37
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell (2010) 6.00
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res (2004) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Cyclin E ablation in the mouse. Cell (2003) 5.58
A critical role for eosinophils in allergic airways remodeling. Science (2004) 5.53
Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron (2009) 5.50
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34